Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Claire Long

- PMLiVE

AstraZeneca’s heart drug impresses, but bleeding risks a concern

Firm still hopes the new Brilinta data can help the medicine be a blockbuster

- PMLiVE

Imbruvica shines in combination trial

Showed significant increase in progression-free survival

- PMLiVE

Political tensions halt Fresenius’ Russian joint venture

Planned to combine subsidiary with Sistema and Zenitco’s CJSC Binnopharm

- PMLiVE

MISSION appoints Paul Wallace as chief business officer

Joins from Medivir where he was executive VP and head of business development

- PMLiVE

Baxter haemophilia drug clears phase III trial

BAX 817 shown to resolve more than 90% of acute bleeds

- PMLiVE

Merck faces another Bridion knockback

It is seven years since the FDA initially rejected it

Nelsons appoints new leadership team to US office

Pat Schneider, John Ende and Brad Baker join the firm

- PMLiVE

Stelara outlook promising for psoriatic arthritis

Likely to be recommended alone and in combination with methotrexate

National Institute for Health and Care Excellence NICE logo

NICE system ‘slowing market access to cancer meds’

Two new reports show that UK access to new treatments and survival rates among lowest in Europe

- PMLiVE

Axon Communications boosts London team with five hires

Lucie Burns, Denis Bilotta, Samantha Treadwell, Karley Ura, Kate Peregrin all new-comers

ABPI London offices

Industry pays £310m to underwrite medicines bills

Latest fourth quarter rebate revealed as pharma looks to ‘underwrite’ the NHS drugs bill

UK flag

Cancer Drugs Fund a ‘missed opportunity’, says MP

Chair of the Liberal Democrat health committee Paul Burstow says the CDF should have gone further

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links